Treatment of Proteinuria Due to Treatment Resistant or Treatment Intolerant Idiopathic Focal Segmental Glomerulosclerosis: A 2 Part Prospective Study of H.P. Acthar Gel (PODOCYTE)

Trial Profile

Treatment of Proteinuria Due to Treatment Resistant or Treatment Intolerant Idiopathic Focal Segmental Glomerulosclerosis: A 2 Part Prospective Study of H.P. Acthar Gel (PODOCYTE)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 Sep 2017

At a glance

  • Drugs Corticotropin (Primary)
  • Indications Proteinuria
  • Focus Therapeutic Use
  • Acronyms PODOCYTE
  • Sponsors Mallinckrodt plc
  • Most Recent Events

    • 25 Sep 2017 Planned End Date changed from 1 Mar 2020 to 1 Jun 2021.
    • 25 Sep 2017 Planned primary completion date changed from 1 Sep 2019 to 1 Jun 2021.
    • 17 May 2016 Status changed from not yet recruiting to recruiting, according to a Mallinckrodt media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top